Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nitric BioTherapeutics
Bristol, Pennsylvania, United Statessciencedirect.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
The company completed several Phase II studies. One demonstrated the ability to deliver high concentrations of terbinafine directly to the nail bed using iontophoresed gel for onychomycosis. Another conducted a multi-arm dose-response trial evaluating gaseous nitric oxide for moderate-to-severe tinea pedes. No recent published results or commercial launches found after these trials.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small moleculeDeviceGas therapy
- Industry
- Biotech
02
Partnerships
NewSpring CapitalQuaker BioVenturesCareFusion/Cardinal Health spinoff
Beyond the preview
Go deeper on Nitric BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nitric BioTherapeutics.